The 5 Most Interesting Analyst Questions From Centene's Q2 Earnings Call

Centene’s second quarter was shaped by unexpected challenges in both its Marketplace and Medicaid businesses, with management openly acknowledging disappointment in the results. CEO Sarah London cited a sharp deterioration in Marketplace risk adjustment revenue and higher medical cost trends in Medicaid as the main drivers behind the non-GAAP loss. The company’s commercial segment faced a significant morbidity shift, attributed to the loss of healthier members and higher utilization among new enrollees, which London called a “disappointing outcome.” In Medicaid, elevated behavioral health, home health, and high-cost drug expenses drove operating margin lower, and management described the quarter’s performance as “unacceptable.”

Is now the time to buy CNC? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Centene’s Q2 Earnings Call

• Josh Raskin (Nephron): asked about Centene’s capital needs for the remainder of the year. CFO Drew Asher explained the company expects to add a net $300 million to subsidiaries and highlighted unused credit facility capacity.

• A.J. Rice (UBS): questioned the assumptions behind marketplace risk adjustment and 2026 repricing. CEO Sarah London detailed that pricing was being updated to reflect the new risk pool, and that market contraction was already being absorbed in 2025.

• Justin Lake (Wolfe Research): inquired about Medicaid guidance and margin improvement. London clarified that targeted interventions in Florida and New York, as well as broader cost control levers, underpin expectations for better margins in the second half.

• David Windley (Jefferies): asked about attrition and morbidity shifts in Marketplace membership. London explained that further attrition is expected in the back half of 2025, with ongoing analysis as more data becomes available in September and December.

• Lance Wilkes (Bernstein): probed Centene’s long-term strategy for risk adjustment payables. London responded that the company would optimize product design and network partnerships, focusing on margin over membership and advocating for market transparency.

Catalysts in Upcoming Quarters

Over the coming quarters, the StockStory team will monitor (1) execution of Marketplace repricing and the impact of rate approvals on membership and profitability; (2) Medicaid rate updates and effectiveness of interventions in high-cost states like Florida and New York; and (3) progress toward Medicare Advantage breakeven, especially as regulatory and policy changes unfold. Additional focus will be placed on detecting early signs of cost containment success and membership stabilization across segments.

Centene currently trades at $26.17, down from $26.77 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.